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Introduction
Gastric carcinoma remains one of the most common
causes of deaths due to malignant neoplasms world-
wide. A rapid increase in the incidence and death rates
caused by this carcinoma was recorded in the second
half of the 20th century. Gastric carcinoma is the sec-
ond, after lung cancer, cause of deaths due to malig-
nancies in the world. Its incidence varies geographi-
cally, being the highest in Japan, China, South Ameri-
ca and much lower in Western Europe and in the USA
[1]. Poland is amongst the countries with the highest
incidence and mortality rates for this carcinoma. In
men, lung cancer is the predominant malignancy,
being the cause of one third of all carcinomas and
deaths due to them. In Poland, like worldwide, gastric
carcinoma, is the second cause of deaths due to malig-
nancy among men. Women most frequently die of can-
cers of the breast, lung, large intestine, ovary and
cervix. Gastric carcinoma is the fifth cause of death in
women [2].
The vast majority of diagnosed and treated gastric
carcinomas are advanced. The lesions surpass the
mucous membrane, invade successive layers of the
gastric wall, and even infiltrate adjacent organs, giv-
ing metastases to local lymph nodes and distant
organs. 
Gastric carcinogenesis is a complex multistep
process resulting from the interaction between genome
and environmental factors. Many exogenous factors
seem to contribute to the initiation of carcinogenesis in
the stomach, including diet, chemical agents and infec-
tions, e.g. caused by Helicobacter pylori and Epstein-
Barr virus [3].
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Abstract: Fhit protein is known to play a role in the process of neoplastic transformation. It has been demonstrated that
FHIT gene inactivation is manifested by a lack or very low concentration of Fhit protein in tissues collected from tumours
in many organs, including head, neck, breast, lungs, stomach or large intestine. The study included a group of 80 patients
with advanced gastric carcinomas. The expression of Fhit protein was assessed by means of the immunohistochemical
method (avidin-biotin-streptavidin) in the sections fixed in formalin and embedded in paraffin, using rabbit polyclonal
antiFhit antibody (Abcam, UK) at 1: 200. Statistical analysis did not show any correlation of the expression of Fhit protein
in the main mass of tumour and in the metastasis to lymph node with gender, depth of wall invasion, histological differen-
tiation, Lauren's classification, Bormann's classification, metastases to local lymph nodes or Helicobacter pylori infection.
However, a strong statistical correlation was revealed of Fhit protein expression in the main mass of tumour with patients'
age (p=0.04) and tumour location in the stomach (p=0.02). No relationship was found between Fhit expression in the main
mass of tumour and survival time (p=0.26). 
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The risk of gastric carcinoma has been shown to
increase seven-fold in patients with H. pylori infection
as compared to non-infected patients. H. pylori exerts
its carcinogenic effect in the stomach via one of two
possible mechanisms: 
1. direct transformation of gastric mucosa via meta-
bolic products,
2. rapid transformation of epithelial cells triggered by
infection-induced mucosal damage, which may
increase the risk of DNA destruction, thus predis-
posing the mucosa to transformation through absorp-
tion or endogenous mutagens and inflammatory bio-
products, e.g. peroxide and hydroxy ions  [4].
The analysis of a tumour suppressor gene, i.a.
FHIT gene, and Fhit protein may help in the search of
factors responsible for the progression of  the neoplas-
tic process.
The FHIT gene is located within the short arm of
chromosome 3 (3q14.2) in FRAB3, being the most frag-
ile site in the human genome [5]. The FHIT gene
encodes a 16.8 kDa protein. The Fhit protein belongs to
the family of Hit proteins (histidine triad), most com-
monly encountered in nature, both in procaryotic and
eucaryotic organisms [6]. The FHIT gene overexpres-
sion in several cell lines leads to apoptosis induction and
proliferation inhibition [7], thus suggesting that the FHIT
gene may play a role in the regulation of cell cycle.   In
humans, the FHIT gene undergoes inactivation in the
early phase of many malignancies, which is usually
reflected by loss of heterozygosity, whereas point muta-
tions of the FHIT gene are very rare [8]. Hypermethyla-
tion of the promotor region is another mechanism
involved in tumour suppressor gene inactivation and has
been observed in e.g. gastric carcinoma [9].
The objective of the current study was to assess
Fhit protein expression in the main tumour mass and
lymph node involvement in advanced gastric carcino-
ma in correlation with chosen clinicopathological fac-
tors, Helicobacter pylori infection and survival time of
patients following tumour resection. 
Materials and methods
Patients. The study was performed on a group of 80 patients (26
women, 54 men), who were surgically treated for advanced gastric
carcinoma in II Department of General Surgery and Gastroenterol-
ogy, Medical University of Bia³ystok, in the years 1998-2003. 
Immunohistochemistry. Formalin-fixed and paraffin-embedded
tissue samples were cut on a microtome to obtain 5 µm thick sec-
tions, which were then deparaffinized in xylenes and rehydrated
through decreasing ethanol concentrations. In order to expose the
antigen, the sections were heated in a pressure cooker in citrate
buffer for 3 min (pH=6.0). Next, they were incubated with 3%
hydrogen peroxide followed by incubation with a rabbit polyclon-
al antiFhit antibody (Abcam, UK) at 1:200 for 60 minutes at room
temperature. After reaction in LSAB (LSAB +System HRP, Dako,
Poland), the antigen-antibody complex was visualized using chro-
mogene DAB (S3000, DAKO, Poland).
Evaluation of samples. Fhit protein expression was evaluated
semiquantitatively and classified as follows:
• 0 – lack of Fhit protein expression in the main mass of tumour
and in metastatic lymph node
• 1 – Fhit expression in 1-30% of the cells assessed in primary
tumour and in metastatic lymph node 
• 2 – Fhit protein expression in above 30% of assessed neoplas-
tic cells.
Statistical analysis. Statistical analysis was performed based on
the χ2 test and exact Fisher's test. The value of p<0.05 was consid-
ered statistically significant. Cox analysis was used to determine
the correlation between Fhit protein expression and survival time
of patients. 
Results
Statistical analysis showed no correlation of Fhit pro-
tein expression with patients' gender, depth of inva-
sion, histological differentiation grade or local lymph
node involvement. Moreover, no relationship was
found between positive immunohistochemical reaction
to Fhit protein and patients' age or tumour location in
the stomach (Table 1). The findings revealed lack of
correlation between the expression of Fhit protein in
the metastatic lymph node and the anatomopathologi-
cal parameters studied (Table 2). Similarly, no statisti-
cally significant correlation was noted between the
expression of Fhit protein in the main mass of tumour
and in the metastatic lymph node (Table 3).
No correlation was found between Fhit protein
expression and survival time. Patients without Fhit
expression or with expression up to 30% were found to
survive approximately 60 months after surgery, where-
as survival rate in the case of tumour Fhit expression
above 30% was about 85 months following surgery.
The difference was not statistically significant
(p=0.26) (Fig. 1). 
Discussion
Neoplastic transformation is a complex multistep
process involving, among others, loss of suppressor
gene functions and oncogene activation. These
changes affect a number of cellular processes: prolif-
eration, genetic stability or cell survival [10].
The short arm of chromosome 3 is one of the most
common sites of chromosomal abnormalities in car-
cinoma. Loss of chromosome 3p alleles has been
described in numerous malignancies, e.g. in the car-
cinoma of the kidney, lungs and breast [4,11]. The
human FHIT gene is located at the FRA3B site of
chromosome 3p14.2. The Fhit protein encoded by
this gene is able to prevent uncontrolled cell prolifer-
ation through a proapoptotic action and inhibition of
cell proliferation. Loss of gene FHIT expression may
have a pivotal role in the pathogenesis of gastric dis-
orders [10,12].
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We found no statistically significant correlation
between the expression of Fhit protein in advanced
gastric carcinoma and such clinicopathological param-
eters as patients' gender, depth of invasion in the gas-
tric wall or histological differentiation grade. Similar-
ly, we found no relationship between the protein
expression and Lauren's and Borman's classifications.
These data are consistent with the findings obtained by
other researchers [13,14,15]. Capuzzi et al. [13] found
no correlation between Fhit protein expression and
Lauren's classification or the rest of parameters. Also
tumour invasiveness did not correlate significantly
with Fhit protein expression. However, they noted 
a significant negative correlation of Fhit protein
expression with tumour stage at the time of diagnosis
and with histological differentiation grade. More
advanced tumours with higher differentiation grade
more frequently showed lack of Fhit protein expres-
sion [15]. Also Naguchi et al. found no relationship
between Fhit protein expression and major prognostic
factors such as pT, pN, infiltration via veins or differ-
entiation grade [11]. On the other hand, Rocco et al.
[9] demonstrated a decrease in Fhit expression or its
lack in most gastric adenocarcinomas, with a statisti-
cally significant correlation in the diffuse type, low
differentiation grade and advanced stage. Changes in
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Table 1. Correlation between Fhit protein expression in the main mass of tumour and chosen clinicopathological parameters in gastric
carcinoma. 
*NS – not statistically significant 
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Table 2. Correlation between Fhit protein expression in lymph node and chosen clinicopathological parameters in gastric carcinoma.
*NS – not statistically significant 
Table 3. Correlation of Fhit protein expression in lymph node with metastasis and in the main mass of tumour in advanced gastric 
carcinoma.
*NS – not statistically significant 
the FHIT gene were directly correlated with a lack of
Fhit expression, and thus the immunohistochemically
examined protein expression appears to be a sensitive
marker of changes in the FHIT gene [9]. 
A statistically significant correlation was observed
between lack or reduction in the expression of Fhit
protein expression and lymph node involvement. No
relationship was found between Fhit expression and
advancement stage and histological differentiation
grade [8]. We did not observe any statistically signifi-
cant correlation between the expression of Fhit protein
in the main mass of tumour and the presence of lymph
node involvement. Among 80 cases assessed in our
study, metastases to local lymph nodes were present in
23. The affected lymph nodes most frequently showed
lack of Fhit protein expression (13 cases), four lymph
nodes displayed Fhit expression in ≤30% and six in
>30% of tumour cells. 
A comparison of a lack of heterozygosity (LOH)
within the FHIT locus with histopathomorphological
features revealed no statistically significant differences
between the histological type and type of growth pat-
tern according to Lauren's classification and WHO
classification [16]. An allelic loss of the FHIT gene,
depending on invasion depth (pT), was observed in
25% of all the early gastric cancers. However, no sig-
nificant correlation was found between LOH frequen-
cies in early gastric cancers (pT1) and advanced gas-
tric cancers (pT2- pT4). Moreover, no relationship was
observed between LOH of the FHIT gene and lymph
node involvement (pN), differentiation grade or inva-
sion through veins. Moreover, LOH of the FHIT gene
did not affect prognosis within various groups of
patients according to Lauren's classification or impor-
tant prognostic parameters such as invasion depth (pT)
and lymph node involvement (pN) [11,14].
We found a statistically significant relationship
between tumour Fhit protein expression and patients'
age. We observed a lack or reduction in the expression
mainly in elderly patients (over 60). Similarly, strong
Fhit expression was also noted in patients aged >60
(20 cases) as compared to patients in the age range ≤60
years (4 cases).
A statistically significant correlation was found
between the expression of Fhit protein in the neoplas-
tic tissue and tumour location in the stomach. We
found the absence of the expression or its reduction in
patients with lesions located in the middle 1/3 part of
the stomach. Strong expression of the protein was
noted mainly in patients with a lesion located in the
lower 1/3 of the stomach or throughout this organ. 
Skopelitou et al. [17] demonstrated a lack or reduc-
tion in the expression of Fhit protein in the inflamma-
tion of gastric mucosa associated with Helicobacter
pylori infection. Negative immunohistochemical stain-
ing, similar in chronic gastric mucosa inflammation
and in gastric adenocarcinomas, was found to strongly
correlate with H. pylori infection and with dysplasia,
but not with intestinal metaplasia or H. pylori activa-
tion grade. Moreover, these investigators showed 
a correlation between lack or reduction in Fhit protein
expression and dysplasia degree or neoplastic progres-
sion. Similarly, Stec-Michalska et al. [18] reported 
a relationship between a decrease in Fhit expression
and the presence of dysplasia or family history of gas-
tric carcinoma, especially in association with Heli-
cobacter pylori. In our study, the lack or reduction in
Fhit protein expression was most common in patients
with high degree of H. pylori infection. These data,
however, were not statistically significant. 
In our study, no correlation was noted between the
lack of Fhit protein expression in the main mass of
tumour and survival time. Patients with strong
immunohistochemical reaction in tumour (>30% of
the cells) were found to live much longer after surgery
as compared to those without Fhit expression in cancer
tissue or with the expression observed in less than 30%
of tumour cells. This difference was significant
(approximately 25 months).
This finding seems to suggest that a lack or reduc-
tion in Fhit protein expression in tumour can be an
unfavourable prognostic factor for patients with
advanced gastric cancers. However, the differences
were not statistically significant.
Similar correlations were observed by Capuzzi et
al. [13]. They found a significant correlation between
Fhit protein expression and survival time of patients
with gastric cancer. Patients with tumour without Fhit
expression died much earlier as compared to those
showing positive reaction to Fhit. Moreover, 
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Fig. 1. Correlation of Fhit protein expression in the main mass of
tumour with survival time of patients with advanced gastric carci-
nomas (p=0.26).
the researchers demonstrated a relationship of tumour
advancement grade with survival time but not with his-
tological differentiation grade. Reduction in Fhit pro-
tein expression was associated with shorter survival
time, irrespective of tumour histological differentia-
tion grade. They also observed a correlation between 
a reduction in Fhit expression in more advanced
tumours and shorter survival time. Higher stage of
tumour advancement may thus indicate unfavourable
prognosis. 
Our findings may suggest that a lack of Fhit protein
expression can be a favourable prognostic factor in
patients with advanced gastric cancer. However, these
data were not statistically significantly correlated. 
References
[ 1] Kelley JR and Duggon JM. Gastric cancer epidemiology and
risk factors. Commentary. J Clin Epidemiology. 2003;56:1-9.
[ 2] Wojciechowska U, Didkowska J, Tarkowski W and Zatoñski
W. Nowotwory z³oœliwe w Polsce w 2003 roku. Centrum
Onkologii-Instytut im. Marii Sk³odowskiej-Curie. Warszawa
2005.
[ 3] Chen J, Chen M, Röcken Ch, Götze, Malfertheiner P and
Ebert MPA. Molecular therapy of gastric cancer. Cancer
Therapy. 2003;1:323-333.
[ 4] Correa P, Ruiz B, Shi TT, Janney A, Sobhan M, Torrado J et
al. Helicobacter pylori and nucleolar organizer regions in
gastric antral mucoas. Am J Clin Pathol. 1994;101:656-660.
[ 5] Hibi K, Takahashi T, Yamakawa K et al. Three distinct
regions involved in 3p deletions in human lung cancer. Onco-
gene. 1992;7:445-449.
52 J. Czy¿ewska et al.
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2009:47(1): 52 (47-53) 
doi: 10.2478/v10042-009-0010-6
Fig. 2. Fhit protein expression in gastric
carcinoma (original magnification ×40)
[ 6] Murhpy GA, Hallday D and McLennan AG. The FHIT tumor
suppressor protein regulates the intracellular concentration of
diadenosine triphosphatase but not diadenosine tetraphos-
phate. Cancer Res. 2000;60:2342-234.
[ 7] Ji L, Fang B, Yen N, Fong K, Minna JD and Roth JA. Induc-
tion of apoptosis and ihibiotoin of tumorigenicity and tumor
growth by adenowirus Victor- medieted fragilehistidine triad
(FHIT) gene overexpression. Cancer Res. 1999;59:3333-
3339.
[ 8] Huebner K and Croce CM. Cancer and the FRAB3B/FHIT
fragile locus: it's a HIT. Br J Cancer. 2003; 88:1501-1506.
[ 9] Rocco A, Schandal L, Chen J, Wang H, Tulassay Z, McNa-
mara D, Malfertheiner P and Ebert MP. Loss of FHIT protein
expression correlates with disease progression and poor dif-
ferentiation in gastric cancer. J Cancer Res Clin Oncol.
2003;129:84-88.
[10] Naylor SL, Johnson BE, Minna JD et al. Los sof heterozy-
gosity of chromosome 3p markers in small cell lung cancer.
Nature. 1987;329:451-454.
[11] Naguchi T, Müller W, Witz HCh, Willers R and Gabbert HE.
FHIT gene in gastric cancer: association with tumour pro-
gression and prognosis. J Pathol. 1999;188:378-381.
[12] Pekarsky Y, Zanesi N, Palamarchuk A, Huebner K and Croce
CM. FHIT: from gene Discovery to cancer treatment and pre-
vention. Oncology. 2002;3:748-754.
[13] Capuzzi D, Santoro E, Hauck WW, Kovatich AJ, Rosato FE,
Baffa R, Huebner K and McCue PA. Fhit expression in gas-
tric adenocarcinoma- correlation with disease stage and sur-
vival. Am Cancer Society. 2000; 88:24-34.
[14] Kawaguchi K, Yashima K, Koda M, Tsutsumi A, Kitajka S,
Andach H, Hosoda A, Kishimoto Y, Shiota G and Murawaki
Y. Fhit expression in human gastric adenomas and intramu-
cosal carcinoma: correlation with Mlh I expression and gas-
tric phenotype. Br J Cancer. 2004;90:672-677.
[15] Lee SH, Kim WH,Kim HK, WooKM, Nam HS,Kim HS, Kim
JG and Cho MH. Altered expression of the fragile histidine
triad gene in primary gastric adenocarcinomas. Bioch Bioph
Res Comm. 2001;284:850- 855.
[16]Huiping C, Kristjansdottir S, Bergthorsson JT, Jonasson JG,
Magnusson J, Egilsson V and Ingvarsson S. High frequency
of LOH, MSI and abnormal expression of FHIT in gastric
cancer. Eur J Cancer. 2002;38:728-735.
[17]Skopelitou AS, Mitselou A, Katsanos KH, Alexopoulou V
and Tsianos EV. Immunohistochemical expression of Fhit
protein in Helicobacter pylori related chronic gastritis, gastric
precancerous lesions and gastric carcinoma: correlation with
conventional clinicopathologic parameters. Eur J Gastroen-
terol Hepatol. 2003;15:515-523.
[18] Stec-Michalska K, Antoszczyk S, Klupnicka G and Nawrot B.
Los sof FHIT expression in gastric mucosa of patients with
family history of gastric cancer and Helicobacter pylori infec-
tion. World J Gastroenterol. 2005;7:17-21. 
Submitted: 30 November, 2008
Accepted after reviews: 27 December 2009
53Expression of Fhit in advanced gastric carcinoma
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2009:47(1): 53 (47-53) 
doi: 10.2478/v10042-009-0010-6
